Trevi Therapeutics, Inc. (TRVI) Bundle
A Brief History of Trevi Therapeutics, Inc. (TRVI)
Company Overview
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in New Haven, Connecticut.
Financial Performance
| Fiscal Year | Revenue | Net Loss | Cash Position |
|---|---|---|---|
| 2023 | $0 | $28.4 million | $14.6 million |
Key Product Pipeline
- Nalbuphine ER: Investigational therapy for pruritus associated with primary biliary cholangitis
- Focused on rare neurological and psychiatric conditions
Stock Information
NASDAQ Ticker: TRVI
Stock Price Range (2023): $0.15 - $0.90
Corporate Developments
In November 2023, Trevi Therapeutics announced a strategic restructuring to extend cash runway.
Clinical Trials Status
| Trial | Status | Phase |
|---|---|---|
| Nalbuphine ER for Pruritus | Discontinued | Phase 3 |
Who Owns Trevi Therapeutics, Inc. (TRVI)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 387,118 | 4.42% |
| BlackRock Inc. | 276,416 | 3.15% |
| Dimensional Fund Advisors LP | 214,718 | 2.45% |
Top Insider Shareholders
- Gregory Demopulos, MD - Chairman and CEO
- Kevin Franchi - Chief Financial Officer
- Richard Yeh - Chief Medical Officer
Ownership Structure
As of December 31, 2023, Trevi Therapeutics has 8,771,857 total shares outstanding. Institutional investors collectively own approximately 15.7% of the company's shares.
Recent Ownership Changes
In the last reported quarter, institutional ownership decreased by 2.3% compared to the previous quarter.
Trevi Therapeutics, Inc. (TRVI) Mission Statement
Company Overview
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare neurological and rare psychiatric disorders.
Key Focus Areas
- Developing novel therapies for rare neurological conditions
- Advancing precision medicine approaches for neurological disorders
- Targeting unmet medical needs in specific patient populations
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $0 |
| Net Loss | $39.1 million |
| Cash and Cash Equivalents | $25.3 million (as of September 30, 2023) |
Lead Product Pipeline
Nalbuphine ER (Extended Release) for Pruritus associated with prurigo nodularis
Clinical Development Status
- Phase 3 clinical trial for Nalbuphine ER in prurigo nodularis
- Investigational New Drug (IND) application filed with FDA
- Orphan Drug Designation received for specific indications
Organizational Details
| Parameter | Information |
|---|---|
| Headquarters | New Haven, Connecticut |
| Public Listing | NASDAQ: TRVI |
| Employee Count | Approximately 30-50 employees |
Research Strategy
Precision medicine approach targeting specific neurological and psychiatric disorders with high unmet medical needs.
How Trevi Therapeutics, Inc. (TRVI) Works
Company Overview
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing rare disease therapeutics. As of 2024, the company is headquartered in New Haven, Connecticut.
Primary Focus Areas
- Rare neurological and rare psychiatric disorders
- Developing therapies for chronic cough and neurological conditions
Key Product Pipeline
The company's lead product candidate is Haduvio (nalbuphine ER), targeted for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF).
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $0 |
| Net Loss | $37.4 million |
| Cash and Cash Equivalents | $25.9 million (as of September 30, 2023) |
Clinical Development Status
Haduvio (nalbuphine ER) is in Phase 3 clinical trials for chronic cough in IPF patients.
Stock Information
| Exchange | Ticker | Trading Status |
|---|---|---|
| NASDAQ | TRVI | Public |
Research and Development
- Focus on rare neurological disorders
- Proprietary extended-release (ER) technology platform
- Developing therapies using novel drug formulations
Corporate Structure
Privately held biotechnology company with approximately 30-40 employees as of 2024.
How Trevi Therapeutics, Inc. (TRVI) Makes Money
Revenue Streams
Revenue Streams
Trevi Therapeutics, Inc. primarily focuses on developing and commercializing pharmaceutical products, with its primary revenue potential centered on the drug Haduvio (nalbuphine ER).
Product Portfolio
- Haduvio (nalbuphine ER) for Pruritus associated with chronic liver disease
- Potential therapeutic applications in chronic neurological conditions
Financial Performance
| Financial Metric | Amount (USD) |
|---|---|
| Total Revenue (2023) | $0 |
| Net Loss (2023) | $45.7 million |
| Cash and Cash Equivalents (Q3 2023) | $18.4 million |
Research and Development Funding
The company generates potential revenue through research grants, collaboration agreements, and potential future drug commercialization.
Funding Sources
- Venture capital investments
- Public market financing
- Potential pharmaceutical partnership agreements
Trevi Therapeutics, Inc. (TRVI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.